35
Participants
Start Date
May 31, 2004
Primary Completion Date
September 30, 2008
Study Completion Date
May 31, 2010
GM-CSF, IFN alpha and IL-2
Treatment during 6 months: GM-CSF, 1 mcg/kg, 3 times per week, subcutaneously, first week of each month; IFN, 10 MIU, 3 times per week, subcutaneously, second week, and IL-2, 1 MIU, 3 tiw, intravenously, third week. Fourth week of each month was free from treatment.
N.N. Blokhin Russian Cancer Research Center, Moscow
Kidney Cancer Research Bureau
OTHER